Author: claramedici

NEW PUBLICATION

Christopher Rohde discuss the use of stimulants in patients with schizophrenia. In a register-based study the authors found that patients with schizophrenia treated with CNS stimulants has a reduced risk of psychiatric admission, fewer days per admission and lower use of antipsychotic medication.  Read more here (in Danish).

Advertisements

NEW PUBLICATION

Christopher Rohde investigated the effects of clozapine in borderline personality disorder. Clozapine was associated with a reduction in psychiatric admissions from 2.52 (95%-CI 2.31-2.78) to 2.00 (95%-CI 1.77-2.23) admissions and a reduction in psychiatric bed-days from 190.08 (95%-CI 176.84-203.33) to 65.95 (95%-CI 58.27-73.66) bed-days. Further, the number of patients with intentional self-harm or overdose decreased significantly from 189 to 114 individuals after clozapine initiation. Read more here.

NEW PUBLICATION

Clara Reece Medici co-authored a study on quality of life and physical health in patients with schizophrenia. The authors found that patients with schizophrenia presented with low quality of life and elevated risk factors for poor physical health. Life style intervention added onto ‘treatment as usual’ improved some risk factors for poor physical health among long-term patients. The number of interventions had an elevating effect on quality of life. Read more here.